-
-
-
-
-
-
-
WHO recommends Regeneron antibody for Bundibugyo Ebola outbreak
-
-
-
-
-
-
-
Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'
-
-
-
-
-
-
-
BofA Securities Reiterates Buy Rating on Regeneron Pharma (REGN)
-
-
-
-
-
-
-
Regeneron (REGN) Tops Q1 EPS by 50c, Beats on Revenue
-
-
-
-
-
-
-
Goldman Sachs sees nearly 140% upside in this biopharma stock
-
-
-
-
-
-
-
Regeneron invests up to $200 million in TriNetX health data partnership
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $890 at Jefferies
-
442,008 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

